bioRxiv Science⌕ Search

Biology subjects

Vogt, T. F.

Publications and source records attributed to Vogt, T. F..

3 recordsLinked to original sources

Global Huntingtin Knockout in Adult Mice Leads to Fatal Neurodegeneration that Spares the Pancreas

Huntingtons disease (HD) is a fatal neurogenerative disorder caused by an expanded glutamine-coding CAG tract in the Huntingtin (Htt) gene. HD is believed to primarily arise via a toxic gain of function, and as a result a wide range of Htt-lowering treatments are in clinical trials. The safety of these trials is contingent on the risks imposed by Htt lowering: Htt is widely conserved, ubiquitously expressed and its complete loss causes severe developmental symptoms in mice and humans. Recently, multiple labs have reported on the consequences of widespread inducible Htt loss in mice. One report describes that early induction of global Htt loss causes fatal pancreatitis, but that later onset lowering is benign. Another study did not report fatal pancreatitis but suggested that postnatal Htt loss was associated with widespread progressive phenotypes, including subcortical calcification and neurodegeneration. To better understand the risks posed by widespread inducible Htt loss we established the phenotypes of mice in which we knocked out Htt with two tamoxifen inducible Cre lines, which we have here extensively characterized. In short, we find that widespread loss of Htt at 2 months of age leads to a wide range of phenotypes, including subcortical calcification, but does not result in acute pancreatitis or histological changes in the pancreas. Additionally, we report here for the first time that Htt loss is followed by robust and sustained increases in the levels of neurofilament light chain (NfL), a peripherally accessible biomarker of neuroaxonal stress. These results confirm that complete loss of Htt in mice is associated with pronounced risks, including progressive subcortical calcification and neurodegeneration.

neuroscience↗

Huntingtin loss in hepatocytes is associated with altered metabolism, adhesion, and liver zonation

Huntingtons disease arises from a toxic gain of function in the huntingtin (HTT) gene. As a result, many HTT-lowering therapies are being pursued in clinical studies, including those that reduce HTT RNA and protein expression in the liver. To investigate potential impacts, we characterized molecular, cellular, and metabolic impacts of chronic HTT lowering in mouse hepatocytes. Lifelong hepatocyte HTT loss is associated with multiple physiological changes, including increased circulating bile acids, cholesterol and urea, hypoglycemia, and impaired adhesion. HTT loss causes a clear shift in the normal zonal patterns of liver gene expression, such that pericentral gene expression is reduced. These alterations in liver zonation in livers lacking HTT are observed at the transcriptional, histological and plasma metabolite level. We have extended these phenotypes physiologically with a metabolic challenge of acetaminophen, for which the HTT loss results in toxicity resistance. Our data reveal an unexpected role for HTT in regulating hepatic zonation, and we find that loss of HTT in hepatocytes mimics the phenotypes caused by impaired hepatic {beta}-catenin function. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=89 SRC="FIGDIR/small/546334v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@1dd0f15org.highwire.dtl.DTLVardef@938f7org.highwire.dtl.DTLVardef@17ae025org.highwire.dtl.DTLVardef@11cd15_HPS_FORMAT_FIGEXP M_FIG C_FIG

cell biology↗

Conformational dynamics and DNA recognition by human MutSbeta

Human and mouse genetic studies have demonstrated a role for DNA mismatch repair (MMR) molecular machines in modulating the rate of somatic expansion of the huntingtin (HTT) CAG repeats, and onset and progression of Huntingtons Disease (HD). MutS{beta}, a key component of the MMR pathway, is a heterodimeric protein of MSH2 and MSH3 that recognizes and initiates the repair of extrahelical DNA extrusions. Loss-of-function of mouse Msh3 and reduced-expression alleles of human MSH3 lead to slower rates of somatic expansion and delayed disease onset in humans, signifying MSH3 as a promising therapeutic target for HD. Here we report biochemical and cryo-electron microscopy analyses of human MutS{beta}, demonstrating MutS{beta} undergoes conformational changes induced by nucleotide and DNA binding. We present multiple conformations of MutS{beta} including the DNA-free MutS{beta} compatible with homoduplex DNA binding, two distinct structures of MutS{beta} bound to (CAG)2 DNA, a sliding clamp form and a DNA-unbound, ATP-bound conformation. Along with evidence for novel conformational states adopted by MutS{beta} to initiate the MMR cascade, these structures provide a foundation for structure-guided drug discovery.

biophysics↗